MRSA Sepsis Mortality Rates: Hospital‑Acquired vs. Community‑Acquired and Key Determinants

Mortality from methicillin‑resistant Staphylococcus aureus (MRSA) bacteremia/sepsis varies substantially by acquisition setting, host factors, and timeliness of appropriate therapy. Reported ranges are estimates from pooled observational data.

Estimated Mortality Ranges

Setting	Approximate 30‑Day / In‑Hospital Mortality
Hospital‑acquired (HA‑MRSA)	25–30%
Healthcare‑associated (HCA‑MRSA)	20–25%
Community‑acquired (CA‑MRSA)	15–20%
Overall pooled	~20–25%

Key Determinants of Outcome

• Source control: Drainage of abscesses, removal of infected devices (catheters, prosthetics) within 24–48 hrs.
• Appropriate empiric therapy: Vancomycin (AUC‑guided), daptomycin, ceftaroline, linezolid; de‑escalate per susceptibilities.
• Host factors: Age, immunosuppression, Charlson comorbidity index, Pitt bacteremia score.
• Infective endocarditis: Presence increases mortality to 30–40%.
• Persistent bacteremia (>3 days): Strong predictor of death.

Prevention & Quality Improvement

• Hand hygiene, contact precautions, chlorhexidine bathing in ICUs.
• Active surveillance cultures in high‑risk units.
• Antimicrobial stewardship to reduce selection pressure.
• Bundle‑based central line and ventilator care.

Early infectious disease consultation improves adherence to guidelines and reduces mortality.